Galcanezumab: clinical trials recruiting now
3
Recruiting trials
7
Conditions studied
1
US states with sites
3
Countries
FDA drug label
- FDA-approved
- Yes. Galcanezumab appears in the FDA drug-label database. Marketed as EMGALITY.
FDA-approved use
EMGALITY ® is a calcitonin-gene related peptide antagonist indicated in adults for the: preventive treatment of migraine. ( 1.1 ) treatment of episodic cluster headache. ( 1.2 ) 1.1 Migraine EMGALITY is indicated for the preventive treatment of migraine in adults. 1.2 Episodic Cluster Headache EMGALITY is indicated for the treatment of episodic cluster headache in adults.
Phase breakdown
Early Phase 1 1
Not applicable 2
Conditions being studied
| Condition | Trials |
|---|---|
| Migraine | 2 |
| Alzheimer Disease | 1 |
| Alzheimer's disease | 1 |
| Anxiety | 1 |
| Chronic Migraine | 1 |
| Depression | 1 |
| Episodic Migraine | 1 |
Recruiting trials involving Galcanezumab
- CGRP Inhibition, Autonomic Function, and Migraine
- Emgality for Migraine in Breastmilk
- Investigator Initiated Trial of Galcanezumab Treatment in Alzheimer's Disease
Common questions
Is Galcanezumab FDA-approved?
Yes, marketed as EMGALITY.
How many recruiting trials involve Galcanezumab?
3 recruiting trials across 7 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.